> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# IQVIA Has Deployed 415 AI Agents, CEO Says, But Sees No Price Cuts From Pharma
- URL: https://www.bullished.co/iqvia-has-deployed-415-ai-agents-ceo-says-but-sees-no-price-cuts-from-pharma-0a9aebdf/
- Published: 2026-10-27T15:13:06.000Z
- Updated: 2026-10-29T17:53:22.000Z
- Description: CEO Ari Bousbib calls AI an added revenue stream in commercial work and a timeline-cutter in trials, not a reason to renegotiate rates.
- Author: Matteo Parrino
- Tags: Earnings, IQV, Industry: Healthcare

[IQVIA](https://www.bullished.co/tag/iqv/), which runs clinical trials and sells healthcare data and analytics to drugmakers, has [deployed 415 AI agents](https://www.benzinga.com/news/26/10/62621415/iqvia-hldgs-q3-2026-earnings-call-transcript?ref=bullished.co) so far, Chairman and CEO Ari Bousbib said on the company's third-quarter earnings call Tuesday. Pressed by an analyst on whether AI will change how pharma pays for its work, he said no.

## AI as extra revenue, not a discount

A Leerink Partners analyst asked whether drugmakers are pushing for value-based contracting, where AI savings get shared. Bousbib said that in the commercial business AI is "essentially an incremental revenue opportunity," sold as added services, agent subscriptions or licenses.

In clinical research, he separated large pharma from biotech. Large pharma rates, he said, were set during the recent renegotiation of strategic partnerships, which "is essentially done." On AI's role in trial pricing talks, he answered "No," calling it "an enabler of faster timelines."

His example: for a large pharma client running several late-stage autoimmune studies across nearly 50 countries, AI-enabled country and site modeling shortened the program by nine months. "[Nine months is](https://www.benzinga.com/news/26/10/62621415/iqvia-hldgs-q3-2026-earnings-call-transcript?ref=bullished.co) huge in this business," he said.

## Generic tools, proprietary content

A Stifel analyst asked what rivals cannot copy. Bousbib said IQVIA builds its agents from generic tools supplied by large AI companies, and spends money with them. The edge, he said, is proprietary data, deep life-sciences context and the ability to interpret results, with "humans in the room" because of healthcare's traceability and compliance demands.

IQVIA is also using agents internally, he said, from finance and HR to software development and testing, which should help its own margin expansion and productivity programs over time.

## A quarter that beat its own guidance

Revenue was [$4.428 billion](https://www.benzinga.com/news/26/10/62621415/iqvia-hldgs-q3-2026-earnings-call-transcript?ref=bullished.co), up 8% as reported and 8.6% at constant currency, above the high end of guidance. Adjusted earnings per share were $3.34, up 11.3%, and adjusted EBITDA margin widened by 20 basis points (0.2 percentage points). Clinical net new bookings reached $3.2 billion, up 15% and the highest in four years.

Chief Financial Officer Michael McDonnell raised full-year guidance for revenue, adjusted EBITDA and adjusted EPS. Revenue is now seen at $17.35 billion to $17.5 billion, and adjusted EPS at $12.90 to $13.00.

## December 1 investor day

IQVIA's market value stood at $45.0 billion in Tuesday trading. McDonnell invited analysts to an investor day on December 1, where management will lay out a framework for next year. Detailed 2027 guidance will come with fourth-quarter results in February 2027.

Bousbib's view of AI's pricing role gets its next airing at the December 1 investor day.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [IQVIA Hldgs Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/10/62621415/iqvia-hldgs-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates](https://finance.yahoo.com/healthcare/articles/iqvia-holdings-iqv-surpasses-q3-111503096.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [IQVIA Non-GAAP EPS of $3.34 beats by $0.06, revenue of $4.43B beats by $60M (IQV:NYSE) | Seeking Alpha](https://seekingalpha.com/news/4657753-iqvia-non-gaap-eps-of-3%5F34-beats-by-0%5F06-revenue-of-4%5F43b-beats-by-60m?ref=bullished.co) — seekingalpha.com
- [IQVIA stock gains as R&D Solutions drive Q3 beat (IQV:NYSE) | Seeking Alpha](https://seekingalpha.com/news/4657864-iqvia-stock-gains-rd-solutions-drive-q3-beat?ref=bullished.co) — seekingalpha.com
- [IQVIA Holdings Inc. (IQV) Stock Price, News, Quote & History](https://ca.finance.yahoo.com/quote/IQV/?ref=bullished.co) — Yahoo Finance

### More on IQVIA Holdings

- [IQVIA Cuts Trial Backlog By $2.1 Billion, Then Refinances 5.0% Notes With 6.375% Debt](https://www.bullished.co/iqvia-cuts-trial-backlog-by-2-1-billion-then-refinances-5-0-notes-with-6-375-debt-10aa97a5/)
- [IQVIA CEO Says He Believes It Won Big In Pharma Contract Reshuffle, While Smaller Rivals 'Lost Out'](https://www.bullished.co/iqvia-ceo-says-he-believes-it-won-big-in-pharma-contract-reshuffle-while-smaller-rivals-bfaafad5/)
- [IQVIA Raises 2026 Outlook As Clinical Bookings Climb 15% To $3.2 Billion](https://www.bullished.co/iqvia-raises-2026-outlook-as-clinical-bookings-climb-15-to-3-2-billion-d290278d/)

[All IQVIA Holdings (IQV) coverage →](https://www.bullished.co/tag/iqv/)